Navigation Links
Celladon Corporation Announces Appointment of Gregg Alton and Graham Cooper to its Board of Directors
Date:9/10/2013

SAN DIEGO, Sept. 10, 2013 /PRNewswire/ -- Celladon Corporation, a clinical-stage biotechnology company focused on developing novel therapies by applying its leadership position in the field of SERCA enzymes, announced today it has appointed Gregg Alton and Graham Cooper to its Board of Directors.

"We are pleased to appoint Gregg and Graham to our Board of Directors," commented Krisztina Zsebo Ph.D., President and CEO of Celladon.  "They each bring extensive experience in the biotechnology industry and we expect they will provide valuable strategic contributions to our Board."

Gregg Alton is currently executive vice president of corporate and medical affairs and chief compliance officer at Gilead Sciences, a position he has held since August 2009.  From 2000 to 2009, Mr. Alton held various positions with Gilead, including associate general counsel, general counsel, vice president and senior vice president.  Earlier in his career, Mr. Alton was an associate at the law firms of Cooley LLP and Mintz, Levin, Cohn, Ferris, Glovsky & Popeo, P.C. where he advised and represented biotechnology clients in a wide range of corporate transactions.  Mr. Alton currently serves on the boards of directors of Gilead Healthcare PAC, the Gilead Foundation, the AIDS Institute and BayBio, a San Francisco life sciences industry organization.  He also serves as a member of the Advisory Board of the University of California, San Francisco Global Health Group and the Dean's Advisory Council at Stanford Law School.  Mr. Alton received a B.A. from the University of California, Berkeley and a J.D. from Stanford Law School. 

Graham Cooper is currently chief financial officer at Receptos Corporation, a biopharmaceutical company focused on therapeutics for immune disorders. Mr. Cooper served as executive vice president of finance and chief financial officer at Geron Corporation during 2012, a biopharmaceutical company focused on cancer therapies.  From 2006 to 2011, Mr. Cooper served as senior vice president, chief financial officer and treasurer of Orexigen Therapeutics, Inc., a biotechnology company focused on obesity therapeutics.  Previously, Mr. Cooper held positions of increasing responsibility, including director, health care investment banking, at Deutsche Bank Securities, a leading global investment bank, where he was responsible for executing and managing a wide variety of financing and merger and acquisition transactions in the life sciences field.  Previously, he worked in audit and accounting services at Deloitte & Touche LLP, an independent registered public accounting firm, and was previously a C.P.A.  Mr. Cooper holds a B.A. in economics from the University of California, Berkeley and an M.B.A. from the Stanford Graduate School of Business. 

About Celladon
We are a clinical-stage biotechnology company applying our leadership position in the field of calcium dysregulation by targeting SERCA enzymes to develop novel therapies for diseases with tremendous unmet medical needs. Sarco/endoplasmic reticulum Ca2+-ATPase, or SERCA, enzymes are a family of enzymes that play an integral part in the regulation of intra-cellular calcium in all human cells. Calcium dysregulation is implicated in a number of important and complex medical conditions and diseases, such as heart failure, diabetes and neurodegenerative diseases. Our therapeutic portfolio for diseases characterized by SERCA enzyme deficiency includes both gene therapies and small molecule compounds. MYDICAR, our most advanced product candidate, uses gene therapy to target SERCA2a, which is an enzyme that becomes deficient in patients with heart failure. In a 39-patient randomized, double-blind, placebo-controlled phase 2a trial in patients with systolic heart failure, which we refer to as CUPID 1, MYDICAR was found to be safe and well-tolerated, reduced heart failure-related hospitalizations, improved patients' symptoms, quality of life and serum biomarkers, and improved key markers of cardiac function predictive of survival, such as end systolic volume. Based on these results, as well as our previous preclinical studies and clinical trials, we advanced MYDICAR to a 200-patient randomized, double-blind, placebo-controlled international Phase 2b trial in patients with systolic heart failure, which we refer to as CUPID 2. We expect to complete enrollment of CUPID 2 in the first quarter of 2014 and announce results in mid-2015.


'/>"/>
SOURCE Celladon Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Celladon Corporation Announces Pre-clinical Study Demonstrating Inhalable MYDICAR Reverses Pulmonary Arterial Hypertension (PAH)
2. Celladon Corporation Selected as Winner of Red Herrings "Top 100 North America Tech Startup"
3. Celladon Corporation and SIRO Clinpharm Announce Presentation at "Statisticians in the Pharmaceutical Industry International Conference"
4. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
5. Celladon Corporation Named a 2012 Fierce 15 Company by FierceBiotech
6. China Cord Blood Corporation Reports Financial Results for the First Quarter of Fiscal 2014
7. China Cord Blood Corporation to Report First Quarter of Fiscal 2014 Financial Results
8. Verenium Corporation To Announce Second Quarter 2013 Financial Results
9. United Therapeutics Corporation Reports Second Quarter 2013 Financial Results
10. Techne Corporation Announces Acquisition Completion
11. United Therapeutics Corporation to Announce Second Quarter 2013 Financial Results Before Market Open on Thursday, July 25, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... The Pittcon 2016 Exposition, ... Georgia, will include 848 exhibitors (count as of February 9) of which 119 ... services used by the scientific community in industrial, academic, and government labs. The ...
(Date:2/11/2016)... DIEGO, Feb. 11, 2016  Neurocrine Biosciences, Inc. (NASDAQ: NBIX ... ended December 31, 2015. --> ... a net loss of $29.3 million, or $0.34 loss per share, ... per share for the same period in 2014. For the year ... $88.9 million, or $1.05 loss per share, as compared to a ...
(Date:2/11/2016)... ATLANTA , Feb. 11, 2016  Wellcentive ... a Portland, Oregon -based community ... to provide population health analytics, quality reporting and ... help FamilyCare strengthen its team of quality managers, ... reporting to the provider groups serving FamilyCare members. ...
(Date:2/11/2016)... ... February 11, 2016 , ... Reichert ... years, continues today to pursue the highest level of accuracy and quality with ... AR9 Refractometer and the AR5 Refractometer. Accurate, reliable and tough enough for ...
Breaking Biology Technology:
(Date:2/8/2016)... , February 8, 2016 ... payment platform which presents innovation for clients, comfort ... feature called VoiceKey. --> Worldcore ... presents innovation for clients, comfort and unbeatable security, ... --> Worldcore is the ...
(Date:2/3/2016)... Vigilant Solutions announces today that the ... Missouri solved two recent hit-and-run cases with ... Vigilant Solutions. Brian Wenberg explains, "I ... was walking out of a convenience store and witnessed an elderly male back ... striking his vehicle and leaving the scene.  In his ...
(Date:2/2/2016)... 2, 2016 Technology Enhancements Accelerate Growth of X-ray ... the digital and computed radiography markets in ... Indonesia (TIM). It provides an ... as well as regional market drivers and restraints. The ... penetration and market attractiveness, both for digital and computed ...
Breaking Biology News(10 mins):